Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024
12 nov. 2024 07h00 HE
|
Medigene AG
Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024
11 nov. 2024 07h00 HE
|
Medigene AG
Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
08 nov. 2024 09h30 HE
|
Medigene AG
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars...
Medigene to Present at Upcoming Investor Conferences
29 oct. 2024 06h30 HE
|
Medigene AG
Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG reports Financial Results and Business Update for Q3 2024
24 oct. 2024 01h30 HE
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
17 oct. 2024 05h30 HE
|
Medigene AG
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Present at Upcoming Scientific Conferences
16 oct. 2024 05h30 HE
|
Medigene AG
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene will Present at ASGCT 2024 and Host R&D Event
02 oct. 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
25 sept. 2024 03h00 HE
|
Medigene AG
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16 sept. 2024 08h30 HE
|
Medigene AG
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...